Telomir-1 restores MASPIN and RASSF1A tumor suppressors in prostate cancer models

Telomir Pharmaceuticals, Inc.

Telomir-1 reversed DNA hypermethylation to reactivate MASPIN and RASSF1A in aggressive prostate cancer models.
MASPIN is a natural defense protein blocking invasion and promoting chemotherapy sensitivity; RASSF1A regulates cell cycle and metastasis suppression.
Dose-dependent reduction in RASSF1A methylation; stronger effect when combined with chemotherapy.
Company continues IND-enabling studies for Telomir-1.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.